$202 Million is the total value of Iguana Healthcare Management, LLC's 69 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 168.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR S&P 500 ETF TRput | $11,787,000 | – | 50,000 | +100.0% | 5.83% | – | |
| CELG | Buy | CELGENE CORP | $11,199,000 | +20.9% | 90,000 | +12.5% | 5.54% | +0.1% |
| SHPG | New | SHIRE PLCsponsored adr | $10,672,000 | – | 61,250 | +100.0% | 5.28% | – |
| MRK | Buy | MERCK & CO INC | $7,943,000 | +22.7% | 125,000 | +13.6% | 3.93% | +1.5% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $7,370,000 | +191.4% | 200,000 | +14.3% | 3.64% | +141.1% |
| AET | New | AETNA INC NEW | $6,378,000 | – | 50,000 | +100.0% | 3.16% | – |
| MRUS | Buy | MERUS N V | $4,268,000 | +34.8% | 175,000 | +16.7% | 2.11% | +11.5% |
| AGN | Buy | ALLERGAN PLC | $4,181,000 | +59.3% | 17,500 | +40.0% | 2.07% | +31.8% |
| KTWO | Buy | K2M GROUP HLDGS INC | $4,102,000 | +36.5% | 200,000 | +33.3% | 2.03% | +12.9% |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $3,531,000 | – | 275,000 | +100.0% | 1.75% | – |
| New | ALEXION PHARMACEUTICALS INCcall | $3,031,000 | – | 25,000 | +100.0% | 1.50% | – | |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $2,648,000 | – | 75,000 | +100.0% | 1.31% | – |
| CAH | New | CARDINAL HEALTH INC | $2,447,000 | – | 30,000 | +100.0% | 1.21% | – |
| IMMU | Buy | IMMUNOMEDICS INC | $2,265,000 | +105.7% | 350,000 | +16.7% | 1.12% | +70.2% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $2,237,000 | +64.8% | 75,000 | +50.0% | 1.11% | +36.4% |
| JUNO | New | JUNO THERAPEUTICS INC | $2,219,000 | – | 100,000 | +100.0% | 1.10% | – |
| TVTY | New | TIVITY HEALTH INC | $2,183,000 | – | 75,000 | +100.0% | 1.08% | – |
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTN | $1,902,000 | +210.3% | 150,000 | +150.0% | 0.94% | +157.1% |
| LHCG | Buy | LHC GROUP INC | $1,887,000 | +37.6% | 35,000 | +16.7% | 0.93% | +13.9% |
| PCRX | New | PACIRA PHARMACEUTICALS INC | $1,824,000 | – | 40,000 | +100.0% | 0.90% | – |
| XENT | Buy | INTERSECT ENT INC | $1,715,000 | +88.9% | 100,000 | +33.3% | 0.85% | +56.2% |
| AKAOQ | Buy | ACHAOGEN INC | $1,514,000 | +132.6% | 60,000 | +20.0% | 0.75% | +92.5% |
| ANAB | New | ANAPTYSBIO INC | $1,388,000 | – | 50,000 | +100.0% | 0.69% | – |
| New | BIOVERATIV INCcall | $1,362,000 | – | 25,000 | +100.0% | 0.67% | – | |
| New | BRISTOL MYERS SQUIBB COcall | $1,360,000 | – | 25,000 | +100.0% | 0.67% | – | |
| CTMX | New | CYTOMX THERAPEUTICS INC | $1,295,000 | – | 75,000 | +100.0% | 0.64% | – |
| EPZM | New | EPIZYME INC | $1,286,000 | – | 75,000 | +100.0% | 0.64% | – |
| IPXL | New | IMPAX LABORATORIES INC | $1,265,000 | – | 100,000 | +100.0% | 0.63% | – |
| New | MEDICINES COcall | $1,223,000 | – | 25,000 | +100.0% | 0.60% | – | |
| DPLO | Buy | DIPLOMAT PHARMACY INC | $1,196,000 | +89.8% | 75,000 | +50.0% | 0.59% | +57.0% |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $1,112,000 | +95.1% | 215,000 | +43.3% | 0.55% | +61.3% |
| ELGX | New | ENDOLOGIX INC | $1,086,000 | – | 150,000 | +100.0% | 0.54% | – |
| ZYNE | New | ZYNERBA PHARMACEUTICALS INC | $1,005,000 | – | 50,000 | +100.0% | 0.50% | – |
| New | MYLAN N Vcall | $975,000 | – | 25,000 | +100.0% | 0.48% | – | |
| New | IMMUNOMEDICS INCcall | $971,000 | – | 150,000 | +100.0% | 0.48% | – | |
| TBPH | New | THERAVANCE BIOPHARMA INC | $921,000 | – | 25,000 | +100.0% | 0.46% | – |
| SCYX | Buy | SCYNEXIS INC | $828,000 | +3.8% | 300,000 | +20.0% | 0.41% | -14.0% |
| SGMO | New | SANGAMO THERAPEUTICS INC | $780,000 | – | 150,000 | +100.0% | 0.39% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $551,000 | – | 75,000 | +100.0% | 0.27% | – |
| AGTC | New | APPLIED GENETIC TECHNOL CORP | $518,000 | – | 75,000 | +100.0% | 0.26% | – |
| New | NEOVASC INC | $505,000 | – | 330,000 | +100.0% | 0.25% | – | |
| OBSV | New | OBSEVA SA | $260,000 | – | 25,000 | +100.0% | 0.13% | – |
| TNDM | Buy | TANDEM DIABETES CARE INC | $120,000 | -25.5% | 100,000 | +33.3% | 0.06% | -38.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.